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Abstract
A small cell-permeable compound,
dehydroxymethylepoxyquinomicin (DHMEQ), does not inhibit
phosphorylation and degradation of IκB (inhibitor of nuclear
factor-κB [NF-κB]) but selectively inhibits nuclear translocation
of activated NF-κB. This study aimed to demonstrate the
antiarthritic effect of this novel inhibitor of the NF-κB pathway in
vivo in a murine arthritis model and in vitro in human synovial
cells. Collagen-induced arthritis was induced in mice, and after
onset of arthritis the mice were treated with DHMEQ (5 mg/kg
body weight per day). Using fibroblast-like synoviocyte (FLS)
cell lines established from patients with rheumatoid arthritis
(RA), NF-κB activity was examined by electrophoretic mobility
shift assays. The expression of molecules involved in RA
pathogenesis was determined by RT-PCR, ELISA, and flow
cytometry. The proliferative activity of the cells was estimated
with tritiated thymidine incorporation. After 14 days of treatment
with DHMEQ, mice with collagen-induced arthritis exhibited
decreased severity of arthritis, based on the degree of paw
swelling, the number of swollen joints, and radiographic and
histopathologic scores, compared with the control mice treated
with vehicle alone. In RA FLS stimulated with tumor necrosis
factor-α, activities of NF-κB components p65 and p50 were
inhibited by DHMEQ, leading to suppressed expression of the
key inflammatory cytokine IL-6, CC chemokine ligand-2 and -5,
matrix metalloproteinase-3, intercellular adhesion molecule-1,
and vascular cell adhesion molecule-1. The proliferative activity
of the cells was also suppressed. This is the first demonstration
of an inhibitor of NF-κB nuclear translocation exhibiting a
therapeutic effect on established murine arthritis, and
suppression of inflammatory mediators in FLS was thought to be
among the mechanisms underlying such an effect.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that affects nearly 1% of the population worldwide and can
lead to significantly impaired quality of life. Mortality rates are
also significantly increased in patients with RA, and currently
available therapies are often unable to change the course of
the disease; therefore, further improvements in therapy are
required. In this regard the recent application of biologic
agents such as monoclonal antibodies to tumor necrosis fac-
tor (TNF)-α and IL-6 receptor, and recombinant soluble TNF-α
receptor have been of great interest. Many cytokines, chemok-
ines, adhesion molecules and matrix degrading enzymes have
been demonstrated to play a role in synovial proliferation and
joint destruction, which are the main pathologic features of RA.
Notably, the efficacy of these biologic agents has indicated
that intervention in a single cytokine pathway can achieve sig-
nificant suppression of the complex inflammatory network and
ameliorate disease. However, there are negative aspects to
therapy with biologic agents, such as opportunistic infections,
infusion reactions, high cost, and the fact that there are someR1348
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biologics. Therefore, further development of small molecular
agents that specifically interrupt the critical intracellular path-
ways that are activated in RA synovium could prove beneficial.
The transcription factor nuclear factor-κB (NF-κB) forms a het-
erodimer or a homodimer of the subunit members, and in the
cytoplasm of unstimulated cells it binds to natural inhibitors of
NF-κB (IκB), which prevent it from entering the nucleus. The
most common activated form of NF-κB in inflammatory cells
consists of a p65 subunit and a p50 or p52 subunit [1-3]. In
synovial tissue from patients with RA, p65 and p50 have been
shown to be present in the nuclei of macrophage-like synovio-
cytes, fibroblast-like synoviocytes (FLS), and vascular
endothelial cells, and probably play a pivotal role in the patho-
genesis of RA [4-7]. The cytokines IL-1 and TNF-α activate
and can be activated by NF-κB, and this positive regulatory
loop amplifies the expression of other cytokines, chemokines,
adhesion molecules, and enzymes in inflamed tissue [2].
Therefore, NF-κB should be considered a primary target for
new types of anti-inflammatory treatments. Indeed, several
recent studies have already shown significant effectiveness of
this strategy. For example, in vivo experiments using murine
arthritic models that employed intra-articular adenoviral gene
transfer of dominant negative IκB kinase β [8] or super repres-
sor IκBα [9], or alternatively intra-articular injection of NF-κB
decoy oligonucleotides [9,10] demonstrated decreased
severity of joint swelling. Moreover, ex vivo adenoviral gene
transfer of IκBα into human synovial tissue inhibited the
expression of inflammatory mediators [11]. Apart from gene
transfer techniques, intravenous injection of a chimeric protein
comprising the super-repressor IκBα fused to the membrane-
transducing domain of the HIV Tat protein was shown to be
effective in a rat model of acute pleuritis, although arthritis was
not addressed in that study [12].
Only a limited number of studies testing the in vivo effects of
small molecular weight compounds on arthritis have been
reported [13]. These include a proteasome inhibitor PS-341
[14], and IκB kinase inhibitors BMS-345541 [15] and SPC
839 [16], which improved clinical and pathologic findings in
murine arthritis. Another NF-κB inhibitor designated
SP100030 was also shown to suppress collagen-induced
arthritis (CIA) [17], but it appeared to be less efficient, possibly
because it selectively affects T cells and not fibroblasts or
endothelial cells. Recently, a peptide inhibitor of NF-κB that
blocks association of NEMO (NF-κB essential modulator) with
IκB kinases has been shown to ameliorate carrageenan-
induced mouse paw inflammation, CIA, and RANKL (receptor
activator of NF-κB ligand)-induced osteoclastogenesis
[18,19].
Because RA is a chronic systemic disease, low molecular
weight, cell-permeable agents that can block the NF-κB path-
way with high specificity – if they become available – may have
an advantage over gene transfer methods. In our search for
such an inhibitor, we designed a compound named dehy-
droxymethylepoxyquinomicin (DHMEQ) using the parent
structure of the antibiotic epoxyquinomicin C. We demon-
strated that DHMEQ inhibits TNF-α-induced nuclear translo-
cation of NF-κB, and does not inhibit phosphorylation and
degradation of IκB, or a c-Jun N-terminal kinase (JNK) and a
caspase-activating pathway in Jurkat T cells [20,21]. Here, we
extended our study to test the therapeutic effect of DHMEQ
on CIA, and to test the efficacy on the inhibition of the inflam-
matory pathway in human RA FLS. The results showed that
this unique inhibitor of NF-κB nuclear translocation may hold
promise for treatment of RA.
Materials and methods
Inhibitor of nuclear factor-κB
DHMEQ was synthesized as described previously [22]. It was
dissolved in 100% dimethyl sulfoxide (DMSO) at 20 mg/ml
and kept in aliquots at -30°C. Before use in cell culture, it was
diluted with the medium described below to a final DMSO
concentration of 0.05% or less, at which no effect of DMSO
per se on NF-κB activity was observed.
Induction of collagen-induced arthritis
Animal experiments were approved by the Institutional Animal
Care and Use Committee of Tokyo Medical and Dental Univer-
sity. Male 8-week-old DBA/1J mice were purchased from Ori-
ental Yeast (Tokyo, Japan). Bovine collagen type II (Collagen
Research Center, Tokyo, Japan) was dissolved in 50 mmol/l
acetic acid at 4 mg/ml and emulsified in an equal volume of
Freund's complete adjuvant (Difco Laboratories, Detroit, MI,
USA). Mice were immunized intradermally with 100 µl of the
emulsion at the base of the tail. After 21 days (day 0) the same
amount of the antigen emulsified in the same adjuvant was
intradermally injected at the base of the tail as a booster immu-
nization. By day 5, 20 out of the 25 mice developed signs of
arthritis and were randomly allocated to two groups of 10 mice
each: an experimental group and a control group. From days 5
to 18, 100 µg DHMEQ (5 mg/kg body weight) dissolved in 50
µl of 100% DMSO was injected subcutaneously every day
into the inguinal region of the mice in the experimental group.
Mice in the control group received 50 µl DMSO, injected
similarly.
Assessment of arthritis
The thickness of each hind paw was measured using a pair of
digital slide calipers by an investigator who was blinded to the
treatment groups. Out of 16 joints in each hind paw (i.e. the
ankle, midfoot, first to fifth metatarsophalangeal [MTP] joints,
interphalangeal joint of the first toe, and second to fifth proxi-
mal and distal interphalangeal joints), the swollen joints were
identified using magnified pictures taken with a digital camera
and counted. Radiographic assessment of bilateral second to
fourth MTP joints was carried out using the following scoring
systems: for soft tissue swelling 0 = not obvious, 1 = mild, 2
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< 0.3 mm in diameter, 2 = erosion > 0.3 mm in diameter. Use
of this system yields a possible score between 0 and 12 per
animal for each item. The left hind paw of each mouse was dis-
sected, formalin-fixed, decalcified, embedded in paraffin, and
stained with hematoxylin and eosin. Synovitis and bone
destruction around the MTP joints of the sections were scored
as follows: synovitis 0 = not obvious, 1 = synovitis < 0.2 mm
at maximum thickness, 2 = synovitis > 0.2 mm at maximum
thickness; bone destruction 0 = not obvious, 1 = obvious
bone erosion, 2 = marked bone erosion associated with pen-
etration of pannus into the marrow space. Radiographic and
histopathologic assessments were performed by five investi-
gators who were blinded to the assignment of mouse groups.
Cell cultures
RA FLS lines were established, as described previously [23],
from the synovial tissues of RA patients obtained at surgery.
RA patients fulfilled the American College of Rheumatology
criteria. All procedures involving human tissues were approved
by the Ethics Committee of Tokyo Medical and Dental Univer-
sity, and consent forms were obtained from the patients
involved in the study. The cells were cultured in 100 mm
dishes with Dulbecco's modified Eagle's medium (high glu-
cose) containing 10% heat-inactivated fetal calf serum (FCS;
Givco, Rockville, MD, USA) and antibiotics. Cells were pas-
saged between four and eight times and were used when the
cultures had reached about 80% cell layer confluence.
RT-PCR
RA FLS in 100 mm dishes were starved for 16 hours in
medium without FCS, and then 10 µg/ml DHMEQ or vehicle
was added. Twenty minutes later they were stimulated with 5
ng/ml TNF-α (PeproTech, London, UK) for 30 minutes,
washed with phosphate-buffered saline (PBS), and detached
from the dishes by treatment with trypsin-EDTA. Total RNA
was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA,
USA) and treated with DNase I (Takara, Ohtsu, Japan), and
RT-PCR was carried out using OneStep RT-PCR Kit (Qiagen)
and the following primers: β-actin (5'-GTCCTCTC-
CCAAGTCCACACA, 3'-CTGGTCTCAAGTCAGTGTACAG-
GTAA), CC chemokine ligand (CCL)5 (formerly called
RANTES; 5'-CGCTGTCATCCTCATTGCTA, 3'-GCT-





CATTT), matrix metalloproteinase (MMP)-3 (5'-
ATGGAGCTGCAAGGGGTGAG, 3'-CCCGTCACCTC-
CAATCCAAG), and vascular endothelial cell growth factor
(VEGF) (5'-ATTGGAGCCTTGCCTTGCTG, 3'-CCAG-
GGTCTCGATTGGATGG). The cycling program was 94°C
for 1 minute, 62°C for 1 minute, and 72°C for 1 minute for 25
or 30 cycles, followed by a final extension for 1 minute. The
PCR products were electrophoresed on 1.5% agarose gel
and stained with ethidium bromide. The relative intensities of
the bands were quantified using image analysis software (NIH
Image version 1.63; National Institute of Health, Bethesda,
MD, USA).
ELISA
RA-FLS were cultured and starved similarly as described
above except 24-well culture plates were used. Twenty min-
utes after addition of DHMEQ (10 µg/ml) or vehicle, TNF-α (5
ng/ml) was added and 24 hours later the supernatant was har-
Figure 1
Clinical effect of NF-κB inhibitor DHMEQ on collagen-induced arthritis in DBA/1J mice-  i i it r  on col agen-induced arthritis in DBA/1J mice. After onset of arthritis, animals were treated with 100 µg/day 
dehydroxymethylepoxyquinomicin (DHMEQ; ■; n = 10) or vehicle (; n = 10). (a) Sum of the thickness of the right and the left hind paws of each 
mouse after 2 weeks of treatment. Each paw was measured twice and the average was plotted. (b) Sum of the number of swollen joints (described 
in the Materials and methods section) in the right and the left hind paws of each mouse after 2 weeks of treatment. Each paw was counted twice and 
the average was plotted. Maximum possible number is 32 per mouse. (c) Change in body weight of each mouse during the first week of treatment. 
Horizontal bars represent the mean. NF-kB, nuclear factor-κB.
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CCL5, IL-1β and IL-6 were purchased from BioSource
(Camacillo, CA, USA), and that for MMP-3 was from MBL
(Nagoya, Japan).
Flow cytometry
RA-FLS were cultured and starved as described above except
60 mm culture dishes were used. Twenty minutes after addi-
tion of DHMEQ (10 µg/ml) or vehicle, TNF-α (5 ng/ml) was
added and 14 hours later the cells were washed with PBS,
detached by trypsin-EDTA, and suspended in PBS. The pre-
pared cells were incubated with monoclonal antibody to inter-
cellular adhesion molecule (ICAM)-1 (BD Sciences, San Jose,
CA, USA), vascular cell adhesion molecule (VCAM)-1 (BD
Sciences), or isotype-matched mouse IgG for 20 minutes, fol-
lowed by a detection with phycoerythrin-conjugated goat anti-
mouse IgG (Southern Biotechnology Associates, Birmingham,
Figure 2
Effect of DHMEQ on radiographic findings in collagen-induced arthritis in mice
in mice. (a) A representative radiograph of the left metatarsophalangeal 
(MTP) joints of a mouse treated with dehydroxymethylepoxyquinomicin 
(DHMEQ), which shows small bone erosions, and (b) that of a control 
mouse, which shows remarkable soft tissue swelling and large bone 
erosions. (c) Soft tissue swelling and (d) bone erosions of bilateral sec-
ond, third and fourth MTP joints observed in the radiographs were 
scored as described in the Materials and methods section. Values are 
expressed as the mean ± standard deviation of the total scores of 10 
mice in each group, determined by five independent observers.
Figure 3
Effect of DHMEQ on histopathologic findings in collagen-induced arthri is in mice
arthritis in mice. (a) A representative specimen of the metatarsophalan-
geal (MTP) joint of a dehydroxymethylepoxyquinomicin (DHMEQ)-
treated mouse, showing almost normal findings, and (b) that of a con-
trol mouse showing remarkable cell infiltration in the synovium and bone 
destruction accompanied by pannus invasion into the marrow space. 
The severity of (c) synovitis and (d) bone destruction in the specimens 
were scored as described in the Materials and methods section. Values 
are expressed as the mean ± standard deviation of the total scores of 
10 mice in each group, determined by five independent observers.
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(Beckman Coulter, Miami, FL, USA).
For detection of apoptotic cells, cells were prepared as above,
DHMEQ (0, 5, or 10 µg/ml) or 1 µmol/l staurosporin (Wako,
Osaka, Japan) was added, the cells were stimulated with TNF-
α (5 ng/ml) 20 minutes later, further incubated for 14 hours,
and stained with Cy3-labeled annexin V (MBL).
Proliferation assay
RA FLS were cultured at a density of 104/well in 96-well cul-
ture plates for 18 hours and then starved for 24 hours in Dul-
becco's modified Eagle's medium with 2 µmol/l 2-
mercaptoethanol, without FCS. After serum starvation, 0–10
µg/ml DHMEQ was added followed 20 minutes later by addi-
tion of 5 ng/ml TNF-α and 5 µCi/ml [3H]thymidine. The cells
were further cultured for 48 hours and incorporation of 3H dur-
ing the last 24 hours was measured in a scintillation counter.
Electrophoretic mobility shift assay
RA FLS were cultured, starved, and stimulated as described
above for RT-PCR, and nuclear extracts were prepared using
NucBaster Protein Extraction Kit (Novagen, Darmstadt, Ger-
many). The protein concentrations of the extracts were esti-
mated by BCA Protein Assay Kit (Pierce, Rockford, IL, USA),
and the extracts were kept at -80°C until use. 32P-labeled oli-
gonucleotide containing the NF-κB binding sequence (5'-
AGTTGAGGGGACTTTCCCAGGC-3') was used as a probe.
Ten micrograms of the nuclear extract was incubated with 2
µg poly(dI-dC) for 30 minutes at room temperature in 20 µl
reaction buffer containing 20 mmol/l HEPES, 20% glycerol,
100 mmol/l KCl, and 0.2 mmol/l EDTA, at pH 7.9. Following
incubation, 32P-labeled probe was added to the mixture with
or without 100-fold excess unlabeled oligonucleotide as a
competitor and incubated for a further 30 minutes at room
temperature. The protein-DNA complexes were separated
from the free probe by 4% PAGE. For supershift assays, 1 µg
of antibody to p50, p52 (Santa Cruz Biotech, Santa Cruz, CA,
USA), or p65 (Chemicon, Temecula, CA, USA) was added to
the sample and incubated for 30 minutes at 4°C before
electrophoresis.
Statistical analysis
Results were compared using two-sided, unpaired Student's
t-tests.
Results
Therapeutic effect of DHMEQ on collagen-induced 
arthritis
The in vivo anti-inflammatory effect of DHMEQ was first dem-
onstrated in a type of CIA model described by Matsumoto and
coworkers [21], in which they showed a prophylactic effect of
this compound when administered at 2–4 mg/kg, three times
a week, from the day of booster immunization, although the
CIA protocol was different from that in the present study and
they did not use adjuvant. To test the therapeutic effect on a
standard CIA model, we included only those mice that had
apparently begun to develop arthritis by day 5 after the
booster immunization with collagen and complete adjuvant,
and started therapy with DHMEQ at 100 µg (5 mg/kg) daily.
After 14 days of therapy (from days 5 to 18), the thickness of
the hind paws in the DHMEQ treated group (mean ± SD; 5.97
± 0.66 mm) was significantly lower than that in the control
Figure 4
Inhibition by DHMEQ of NF-κB in rheumatoid arthritis fibroblast-like synoviocytes. Nuclear extracts were obtained from unstimulated and tumor 
necrosis factor (TNF)-α-stimulated rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) and nuclear factor-κB (NF-κB) DNA-binding activity 
was examined by electrophoretic mobility shift assays. For supershift assays, the DNA-protein mixture was incubated with antibodies to p65, p50, or 
p52 before electrophoresis. To confirm the specificity of the assay, 100-fold excess of unlabeled NF-κB probe was included as a competitor. To 
assess whether dehydroxymethylepoxyquinomicin (DHMEQ) inhibits NF-κB activation in RA FLS, the cells were incubated with DHMEQ for 20 min-
utes before the stimulation with TNF-α. Data shown are representative of three independent experiments.
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The number of swollen joints was also significantly lower in the
DHMEQ-treated group (9.20 ± 4.64 versus 14.20 ± 3.68; Fig.
1b). During the first week of treatment, these young animals
exhibited growth retardation, as estimated from their body
weights, likely resulting from severe inflammation. However,
this slow-down was significantly less in the DHMEQ group
(weight gain from days 5 to 12; 1.29 ± 1.25 g) than in the con-
trol group (0.14 ± 1.01 g; Fig. 1c), suggesting that DHMEQ
alleviated inflammation and was tolerable at the dose tested.
Radiographs showed various degrees of soft tissue swelling
and destructive changes in bone (Fig. 2a, b). The scores of
these findings were both significantly lower in the group
treated with DHMEQ (Fig. 2c, d). At the histologic level, vari-
ous degrees of synovitis and bone destruction were observed
(Fig. 3a, b). In severe cases, marked infiltration of mononuclear
cells were present within the synovium, and pannus was fre-
quently observed to penetrate into the bone marrow space.
Again, DHMEQ reduced these findings significantly (Fig. 3c,
d).
Inhibition of nuclear factor-κB in rheumatoid arthritis 
fibroblast-like synoviocytes by DHMEQ
To examine the mechanisms underlying the antiarthritic effect
of DHMEQ, as well as its effect on human cells, RA FLS lines
were established from several patients with RA and used for
the present experiments. We should like to note that it was
previously confirmed that these cells expressed neither CD14
nor HLA class II [23], which means that they did not contain
either macrophages or dendritic cells.
The effect of DHMEQ on NF-κB activation in RA FLS was
examined using electrophoretic mobility shift assay (Fig. 4).
Unstimulated RA FLS in serum-free medium exhibited only a
faint band corresponding to NF-κB, but stimulation with 5 ng/
ml TNF-α increased the intensity of the band dramatically. In
Figure 5
Effect of DHMEQ on inflammatory mediator mRNA expression by RA FLS stimulated with TNF-α. (a) Five rheumatoid arthritis (RA) fibroblast-like 
synoviocyte (FLS) cell lines (#1–#5) obtained from different patients were stimulated with tumor necrosis factor (TNF)-α in the presence or absence 
of 10 µg/ml dehydroxymethylepoxyquinomicin (DHMEQ) and mRNA expression of CC chemokine ligand (CCL)2, CCL5, IL-6, IL-1β, matrix metallo-
proteinase (MMP)-3, and vascular endothelial cell growth factor (VEGF) was examined by RT-PCR. (b) Densitometric analysis of these results. Inten-
sity of each band was normalized relative to that of β-actin in the same lane, and the mean ± standard deviation of the five cell lines are shown. *P < 
0.05 versus T. D, DHMEQ; T, TNF-α.
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band of NF-κB, and anti-p65 antibody also remarkably dimin-
ished the intensity of the band. Anti-p52 antibody was much
less effective, suggesting that the major components of the
activated NF-κB in TNF-α-stimulated RA FLS were p65 and
p50. An excess amount of unlabeled NF-κB probe abolished
the band, confirming the specificity of this assay. When
DHMEQ was added 20 minutes before the stimulation with
TNF-α, the band representing NF-κB was abrogated almost
completely at 10 µg/ml but not significantly at 1 µg/ml. Based
on these findings, the following experiments were carried out
using 10 µg/ml DHMEQ unless otherwise indicated.
Suppression of inflammatory mediators by DHMEQ
Among the many molecules that are involved in inflammatory
responses, a set of representative chemokines, ILs, MMP-3,
and VEGF were selected to test the effect of DHMEQ. IL-6 is
known to be an NF-κB-dependent cytokine [24,25] and is one
of the key cytokines in RA pathogenesis, as evidenced by the
fact that an anti-IL-6 receptor monoclonal antibody has been
shown to reduce significantly RA disease activity in clinical tri-
als [26]. We previously showed that chemokines CCL2 and
CCL5 play a role not only in inflammatory cell migration but
also in activation of RA FLS in an autocrine or paracrine man-
ner [23]. Other investigators have shown that an antagonist to
CCL2 suppressed arthritis in a murine model [27]. MMP-3 is
among the cartilage-degrading enzymes and is known to be
regulated by the NF-κB pathway in RA synovium [28]. VEGF
is one of the angiogenic factors that are involved in the neo-
vascularization in RA joints [29].
The effect of DHMEQ on mRNA expression of these key mol-
ecules was first examined by RT-PCR. As shown in Fig. 5,
there was some heterogeneity in the mRNA expression levels
depending on the cell line used. However, mRNA levels of
CCL2, IL-6, and MMP-3 tended to be consistently increased
by TNF-α stimulation and suppressed by DHMEQ. CCL5
mRNA was not detected in one of the cell lines (#5), but in
other cell lines it was enhanced by TNF-α and suppressed by
DHMEQ. IL-1β mRNA was barely detectable in some of the
cell lines tested, at least under these assay conditions. How-
ever, after TNF-α stimulation IL-1β mRNA was clearly
expressed in cell line #2 and faintly in lines #1 and #5; in all
cases the expression was diminished by treatment with
DHMEQ. In contrast, the level of VEGF mRNA was neither sig-
nificantly increased by TNF-α nor suppressed by DHMEQ. We
applied a constant amount of RNA to each tube, and observed
virtually constant intensity of β-actin mRNA, irrespective of
treatment with DHMEQ; this suggested that this compound
did not affect the housekeeping activity of the cells.
Figure 6
Suppressive effect of DHMEQ on inflammatory mediator production by RA-FLS at the protein leveli l l. Rheumatoid arthritis (RA) fibroblast-like synovio-
cytes (FLS) were stimulated with tumour necrosis factor (TNF)-α in the presence or absence of 10 µg/ml dehydroxymethylepoxyquinomicin 
(DHMEQ), and levels of secreted CC chemokine ligand (CCL)2, CCL5, IL-6, and matrix metalloproteinase (MMP)-3 in the culture supernatants were 
measured using ELISA. Values are expressed as the mean ± standard deviation of three independent experiments.
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expression of CCL2, CCL5, IL-1β, IL-6 and MMP-3 was fur-
ther tested at the protein level by ELISA (Fig. 6). CCL2, CCL5
and IL-6 were barely detected in the serum-free culture super-
natant of the cells unless the cells were stimulated, but were
produced abundantly after TNF-α stimulation. This production
was significantly suppressed by DHMEQ. Similarly, produc-
tion of MMP-3 tended to be suppressed by DHMEQ, although
this was not statistically significant. Because the level of IL-1β
was lower than the detection limit (10 pg/ml), even after stim-
ulation with TNF-α, we could not confirm the effect of DHMEQ
on IL-1β expression by ELISA.
Suppression of adhesion molecule expression by 
DHMEQ
Adhesion molecules ICAM-1 (CD54) and VCAM-1 (CD106)
are expressed at higher levels in the synovial tissue of RA than
in osteoarthritis [30,31] and are implicated in the interaction
between leukocytes and RA FLS that contributes to the syno-
vitis. Flow cytometric analysis showed that 2.7 ± 0.5% (mean
± standard deviation [SD] of four independent experiments) of
RA FLS expressed ICAM-1 in serum-free medium, and the
ratio of cells expressing ICAM-1 markedly increased up to
44.5 ± 11.7% after stimulation with TNF-α (Fig. 7). In the
presence of DHMEQ, however, this ratio significantly
decreased to 5.3 ± 3.4%. On the other hand, VCAM-1 was
expressed on only 0.9 ± 1.0% (mean ± SD of three independ-
ent experiments) of the unstimulated cells, but 29.0 ± 11.2%
of the cells expressed VCAM-1 after TNF-α stimulation (Fig.
8); this ratio significantly decreased to 3.1 ± 2.5% by the
effect of DHMEQ.
Suppression of proliferative activity of rheumatoid 
arthritis fibroblast-like synoviocytes by DHMEQ
One of the prominent characteristics of RA FLS is their prolif-
erative activity, which leads to pannus formation as well as
swelling of the joints, and pathways controlling the prolifera-
tion of RA FLS include an NF-κB-dependent pathway [32].
Representative data shown in Fig. 9 indicate that RA FLS
incorporate a certain amount of [3H]thymidine even without
stimulation (mean ± SD; 207 ± 36 counts/minute), which was
significantly higher than the background level (29 ± 1.2
counts/minute; P < 0.01). This moderate activity increased to
582 ± 53 counts/minute with stimulation with TNF-α, and
DHMEQ significantly suppressed this proliferative activity in a
dose-dependent manner. At 5.0 µg/ml or higher concentration
of DHMEQ, proliferative activity of the cells was lower than
that of unstimulated cells, suggesting that DHMEQ sup-
pressed spontaneous proliferation as well as TNF-α-induced
proliferation.
Cytotoxic effect of DHMEQ on rheumatoid arthritis 
fibroblast-like synoviocytes
To test whether DHMEQ exhibits cytotoxicity at the concentra-
tion that suppressed inflammatory mediators, serum-starved
RA FLS were further incubated for 14 hours after stimulation
with TNF-α in serum-free medium with DHMEQ or the apopto-
sis inducer staurosporin. Thereafter, expression of annexin V
binding phospholipid on the cell surface – an indicator of early
phase of apoptosis – was measured using Cy3-labeled
annexin V. With staurosporin, 10.1% of the cells were annexin
V positive and the mean fluorescence intensity was 1.1 (Fig,
10). In contrast, in the presence of 5 and 10 µg/ml DHMEQ,
the ratio and mean fluorescence intensity of annexin V positive
Figure 7
Suppression of ICAM-1 expression by DHMEQi  . Shown, using flow cytometry, is suppression of intercellular adhesion molecule (ICAM)-1 expressed 
on tumor necrosis factor (TNF)-α-stimulated rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) by dehydroxymethylepoxyquinomicin 
(DHMEQ). Cells were preincubated for 20 minutes with 10 µg/ml DHMEQ or vehicle. TNF-α stimulated or unstimulated RA FLS were incubated 
with isotype-matched control IgG or anti-ICAM-1 antibody, followed by phycoerythrin-labeled second antibody. (a) Representative data are shown, 
along with (b) the means ± standard deviation of ICAM-1-positive cells in four independent experiments.
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R1356cells remained less than 1% and 0.5%, respectively. Trypan
blue dye exclusion test also showed virtually 100% viability of
the cells incubated with DHMEQ (not shown).
Discussion
Many stimuli are known to activate NF-κB, including TNF-α, IL-
1β, anti-CD3 antibody (in T cells), oxidative stresses, viral
products and lipopolysaccharides, and these act by means of
protein kinases that phosphorylate IκB, leading to degradation
of IκB by the proteasome and passage of NF-κB into the
nucleus [2]. NF-κB regulates the expression of many genes
that are involved in inflammatory responses, including TNF-α,
IL-1β, IL-6, CCL2, CCL5, MMP-3, ICAM-1, VCAM-1, inducible
nitric oxide synthase, and cyclo-oxygenase-2, all of which are
known to participate in the pathogenesis of RA. Products of
these genes coordinately enhance inflammatory reactions
resulting in further activation of NF-κB. In fact, NF-κB compo-
nents p50 and p65 were demonstrated to be activated in both
macrophage-like and fibroblast-like synoviocytes as well as
vascular endothelial cells in RA-derived synovial tissue but not
in normal synovium [4-7]. In RA synovium p50 and p65 expres-
sion increases, especially at sites adjacent to the cartilage-
pannus junction, and is thought to be implicated in cartilage
destruction [33]. It is clear, therefore, that NF-κB is an impor-
tant target molecule for RA therapy. Aspirin, sodium salicylate,
corticosteroids, sulfasalazine, and gold salts were demon-
strated, at least in part, to exhibit their activity by way of NF-κB
suppression [34-37], and novel agents that are more specific
to the NF-κB pathway than these classical agents – and are
less costly than the recently marketed biologics – would be of
great value. Indeed, inhibition of the NF-κB pathway by gene
therapy [8-11] or by small molecular weight compounds [13-
Figure 8
Suppression of VCAM-1 expression by DHMEQ. Suppression of vascular cell adhesion molecule (VCAM)-1 expressed on tumor necrosis factor 
(TNF)-α-stimulated rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) by dehydroxymethylepoxyquinomicin (DHMEQ). Flow cytometric anal-
ysis was carried out (as in Fig. 7) except that anti-VCAM-1 antibody was used. (a) Representative data are shown, along with (b) the means ± stand-
ard deviation of VCAM-1-positive cells in three independent experiments.
Figure 9
Suppression of proliferative activity of RA FLS by DHMEQti it  f  FLS by DHMEQ. Rheumatoid 
arthritis (RA) fibroblast-like synoviocytes (FLS) were stimulated with 
tumor necrosis factor (TNF)-α or unstimulated in the presence or 
absence of dehydroxymethylepoxyquinomicin (DHMEQ), cultured for 
48 hours, and incorporation of [3H]thymidine during the last 24 hours 
was measured. Values are expressed as mean ± standard deviation of 
triplicate measurements. Data shown are representative of three inde-
pendent experiments. *P < 0.01, **P < 0.001. cpm, counts/minute.
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R135718] has recently been tested in experimental models of arthri-
tis, demonstrating the efficacy of this strategy.
We previously showed that DHMEQ does not inhibit phos-
phorylation and degradation of IκB, but inhibits nuclear
transport of p65 in TNF-α-stimulated COS-1 cells transfected
with the DNA that encodes p65 combined with green fluores-
cent protein [20]. It does not affect TNF-α-induced activation
of JNK, or nuclear transport of Smad2 or the large T antigen.
This molecule should therefore be considered a unique inhibi-
tor of NF-κB that acts at the level of nuclear translocation. This
specificity is an advantage of DHMEQ over the inhibitors of the
upstream molecules of the NF-κB pathway, because kinase
inhibitors or proteasome inhibitors may suffer from
disadvantages relating to specificity and undesired effects
that are unrelated to the NF-κB pathway. Another advantage
of DHMEQ over gene transfer methods is its simplicity of
administration. In our model of mouse arthritis, subcutaneous
daily injections of 5 mg/kg DHMEQ resulted in a significant
therapeutic effect on arthritis. Although the efficacy of other
administration protocols and the pharmacokinetics of DHMEQ
remain to be studied in detail, small, cell-permeable com-
pounds appear to have fewer obstacles to be overcome in
comparison with gene transfer strategies because RA is a
chronic systemic inflammatory disorder.
As a first step toward application in human cells, we tested the
effect of DHMEQ on the function of RA synovial cells in cul-
ture. Thus far, studies that showed effects of NF-κB inhibitors
using human synovial cells have been limited. However, sup-
pression of expression of the key inflammatory cytokine IL-6,
chemokines CCL2 and CCL5, matrix-degrading enzyme
MMP-3, and adhesion molecules ICAM-1 and VCAM-1, as
well as proliferative activity of the cells, suggested that
DHMEQ may be efficacious in the treatment of RA synovitis.
In the electrophoretic mobility shift assay, 10 µg/ml DHMEQ
nearly completely inhibited NF-κB activity of the TNF-α-stimu-
lated RA FLS, but its effect was not significant at 1 µg/ml (Fig.
Figure 10
Cytotoxicity of DHMEQ. Significant cytotoxicity was not observed in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) treated with dehy-
droxymethylepoxyquinomicin (DHMEQ). Cells were stimulated with 5 ng/ml tumor necrosis factor (TNF)-α and incubated in serum-free medium for 
14 hours with 0–10 µg/ml DHMEQ or with the apoptosis inducer staurosporin (1 µmol/l), and Cy3-labeled annexin V binding cells were measured 
by flow cytometry. Data shown are representative of three independent experiments. MFI, mean fluorescence intensity.
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R13584). Nevertheless, in the proliferation assay 1.3 µg/ml DHMEQ
significantly suppressed TNF-α-stimulated thymidine uptake
by RA FLS (Fig. 9). Variation is to a certain extent inevitable in
experiments using RA FLS, but this discrepancy was repro-
ducible. It seems possible, in assays that require longer incu-
bation of cells, that secondary effects of NF-κB inhibition
resulting from suppressed expression of cytokines and other
regulatory molecules of cellular activity may merge with the
direct effect of DHMEQ.
VEGF is thought to promote angiogenesis and enhance vas-
cular permeability in inflamed tissue, but we did not observe
suppression of VEGF mRNA expression by DHMEQ. A recent
investigation showed suppression of IL-6-induced VEGF pro-
duction by fibroblasts using a JNK inhibitor, which suggests
that expression of VEGF is predominantly regulated not by the
NF-κB pathway but by the activator protein-1 pathway [38]. In
this regard, it was reported that cyclosporin A, which is a
widely used immunosuppressant and is effective to some
degree in RA, suppressed expression of VEGF by RA-FLS by
way of suppressing activator protein-1 binding activity [29].
The most important goal in RA therapy is the prevention of
bone destruction in order to maintain normal function of the
joints. It was recently demonstrated that DHMEQ suppresses
osteoclastogenesis in a culture system of mouse bone marrow
derived macrophage precursor cells stimulated with RANKL
(receptor activator of NF-κB ligand) and macrophage colony-
stimulating factor, and suppresses the bone-resorbing activity
of mature osteoclasts [39]. Therefore, it is of interest to study
further the in vivo effect of this inhibitor on bone-resorbing
activity in severe arthritis.
Along with efficacy, safety issues should be addressed. In the
present study we observed no abnormality in the behavior of
the mice treated with DHMEQ; rather, they exhibited less
weight loss than did the control mice during the active period
of inflammation. In in vitro experiments, annexin V staining and
trypan blue staining confirmed that cell viability did not
decrease. The mRNA expression of VEGF and β-actin was not
affected by DHMEQ. However, NF-κB is known to play a role
in preventing cell apoptosis [40]. Massive hepatocyte apopto-
sis in p65-deficient mice is an extreme example of the antiap-
optotic role of NF-κB [41]. We also observed significant
apoptosis in some tumor cells transplanted into nude mice
treated with DHMEQ (8 mg/kg per day, by intraperitoneal
injection), but the mice did not exhibit adverse effects [42].
The relationship between the anti-inflammatory effect of
DHMEQ and apoptosis of cells in inflamed as well as normal
tissue remains to be further examined.
Conclusion
We showed herein that an NF-κB nuclear translocation inhib-
itor DHMEQ had a therapeutic effect on CIA in mice, and sup-
pressed the expression of inflammatory molecules and the
proliferative activity of TNF-α-stimulated RA FLS. Although its
effect on other human cell types, especially T cells, vascular
endothelial cells and osteoclasts, are currently under
investigation, these findings suggest that FLS are among the
important targets on which DHMEQ exerts its antiarthritic
effect. This agent may be a promising candidate for further
clinical development.
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